Ji-Ae Park1, Jung Young Kim1,
Byoung Soo Kim1, Wonho Lee1, In Ok Ko1, Joo
Hyun Kang1, Sang Moo Lim2, Hee-Kyung Kim3,
Yongmin Chang3, Tae-Jeong Kim4, Kyeong Min Kim1
1Molecular Imaging Research
Center, Korea Institute of Radiological & Medical Science, Seoul,
Nowon-Gu, Korea, Republic of; 2Department of nuclear Medicine,
Korea Institute of Radiological & Medical Science; 3Department
of Medical & Biological Engineering, Kyungpook National University; 4Department
of Applied Chemistry, Kyungpook National University, Korea, Republic of
The combination of magnetic resonance imaging (MRI) and nuclear medicine imaging can be representative synergistic approach for providing anatomical and functional information together, because of the high resolution of MRI and the high detector sensitivity of radionuclide imaging, respectively. In this study, we report the Gd-DTPA-histidine conjugated of 99mTc complexes [GdLHis_99mTc] as MR/SPECT dual modality contrast agents. To overcome problems in hybrid imaging due to the huge difference (~103) of imaging sensitivity between MRI and SPECT, we suggest the mixed-usage of [GdLHis_99mTc] with Gd-DTPA-histidine conjugated of Re complexes [GdLHis_Re] that is an alternative substance(cold-form) having chemical characteristics equivalent with [GdLHis_99mTc]. A new hybrid 99mTc labeled MR contrast could be made and be suitable to both MRI and SPECT imaging. The identical characteristics of [GdLHis_99mTc] and [GdLHis_Re] showed the same bio-functional change of hybrid contrast agents, with the additional merit of improved MRI image quality. Therefore, the hybrid-usage of both [GdLHis_Re] and [GdLHis_99mTc] should be useful in the optimal acquisition of MR/SPECT imaging that is prerequisite for precise interpretation of bio-function.